• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.

作者信息

Hoppel C, Garle M, Rane A, Sjöqvist F

出版信息

Clin Pharmacol Ther. 1977 Mar;21(3):294-300. doi: 10.1002/cpt1977213294.

DOI:10.1002/cpt1977213294
PMID:837648
Abstract

A mass fragmentographic method was used to determine unconjugated and conjugated 5-(4-hydroxyphenyl)-5-phenylhydantonin (4-OH-DPH) in plasma of patients being treated with phenytoin (DPH). The plasma concentration of unconjugated 4-OH-DPH is stable at steady-state for DPH and the level does not change during the dose interval. Most patients (82.5%) have plasma concentrations of unconjugated 4-OH-DPH between 0.04 and 0.2 mug/ml at concentrations of DPH between 5 and 30 mug/ml. Interindividual differences in the ratio between plasma concentration of unconjugated 4-OH-DPH and DPH were noted in a wide range of doses. Dosage adjustments of DPH in patients were not associated with major changes in the plasma level of unconjugated 4-OH-DPH. The plasma concentration of conjugated 4-OH-DPH also showed interindividual differences and varied between 1.2 and 4.5 mug/ml in patients with DPH concentrations between 5 and 30 mug/ml. The data are consistent with the concept of Michaelis-Menten kinetics for DPH metabolism.

摘要

相似文献

1
Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
Clin Pharmacol Ther. 1977 Mar;21(3):294-300. doi: 10.1002/cpt1977213294.
2
Loading and conventional dose therapy with phenytoin in children: kinetic profile of parent drug and main metabolite in plasma.儿童苯妥英钠的负荷剂量及常规剂量治疗:血浆中母体药物及主要代谢物的动力学特征
Clin Pharmacol Ther. 1976 Jul;20(1):48-58. doi: 10.1002/cpt197620148.
3
Phenytoin metabolism in pregnancy.
Obstet Gynecol. 1980 Nov;56(5):577-82.
4
Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure.
Clin Pharmacol Ther. 1979 Sep;26(3):306-14. doi: 10.1002/cpt1979263306.
5
Mass fragmentographic determination of diphenylhydantoin and its main metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, in human plasma.人体血浆中苯妥英及其主要代谢物5-(4-羟苯基)-5-苯乙内酰脲的质量碎片分析法测定
J Chromatogr. 1976 Jan 7;116(1):53-61. doi: 10.1016/s0021-9673(00)83699-7.
6
Stable-isotope methodology for the bioavailability study of phenytoin during multiple-dosing regimens.
J Pharm Sci. 1985 May;74(5):503-7. doi: 10.1002/jps.2600740503.
7
Use of stable isotopes in the study of pharmacokinetics of drugs by mass fragmentography II: Detailed examination of pharmacokinetics of a single oral dose of phenytoin in humans.稳定同位素在药物动力学研究中通过质量碎片谱法的应用II:单剂量苯妥英钠口服给药后人体药物动力学的详细研究
J Pharm Sci. 1980 Nov;69(11):1300-7. doi: 10.1002/jps.2600691118.
8
Assay of the major (4-hydroxylated) metabolites of diphenylhydantoin in human urine.人尿中苯妥英主要(4-羟基化)代谢物的测定。
Eur J Clin Pharmacol. 1975 Jun 13;8(5):359-63. doi: 10.1007/BF00562663.
9
Phenytoin metabolism in mice.
Drug Metab Dispos. 1982 Mar-Apr;10(2):156-60.
10
Metabolism of diphenylhydantoin (phenytoin) during pregnancy.
Br J Obstet Gynaecol. 1979 Feb;86(2):125-32. doi: 10.1111/j.1471-0528.1979.tb10579.x.

引用本文的文献

1
Hepatic Bioactivation of Skin-Sensitizing Drugs to Immunogenic Reactive Metabolites.皮肤致敏药物向免疫原性反应性代谢物的肝脏生物活化作用。
ACS Omega. 2019 Aug 12;4(9):13902-13912. doi: 10.1021/acsomega.9b01551. eCollection 2019 Aug 27.
2
Phenytoin immunoassay measurements in serum samples from patients with renal insufficiency: comparison with high-performance liquid chromatography.肾功能不全患者血清样本中苯妥英免疫测定法测量结果:与高效液相色谱法的比较
J Clin Lab Anal. 2007;21(2):119-23. doi: 10.1002/jcla.20115.
3
The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.
将EMIT FreeLevel超滤技术与平衡透析法和超速离心法进行比较,以测定苯妥英的蛋白结合率。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:61-70. doi: 10.2165/00003088-198400091-00008.
4
Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.抗惊厥药物活性代谢物的形成。其药代动力学及治疗意义综述。
Clin Pharmacokinet. 1991 Jul;21(1):27-41. doi: 10.2165/00003088-199121010-00003.
5
Rate of phenytoin accumulation in man: a simulation study.
J Pharmacokinet Biopharm. 1978 Oct;6(5):399-415. doi: 10.1007/BF01062722.
6
Clinical pharmacokinetics of phenytoin.苯妥英钠的临床药代动力学
Clin Pharmacokinet. 1979 May-Jun;4(3):153-69. doi: 10.2165/00003088-197904030-00001.